Neuren Pharmaceuticals 

Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for Rett syndrome, and has also successfully completed Phase II trials targeting Fragile X syndrome. The company is also progressing NNZ-2591, which has finished its initial human trials (Phase I) for a spectrum of rare neurodevelopmental disorders, including Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Willi syndromes. In addition to its drug pipeline, Neuren provides development-related services and possesses investments in loan-backed shares. The firm was established in 2001 and operates from its base in Camberwell, Australia.